Presentation is loading. Please wait.

Presentation is loading. Please wait.

AXL is not necessary for maintenance of intrinsic resistance.

Published byEvelyn Mosley Modified over 5 years ago

Similar presentations

Presentation on theme: "AXL is not necessary for maintenance of intrinsic resistance."— Presentation transcript:

1 AXL is not necessary for maintenance of intrinsic resistance.
AXL is not necessary for maintenance of intrinsic resistance. A, effects of AXL overexpression on survival of drug-sensitive BRAFV600-mutant melanoma cell lines following 4-day treatment with PLX4720 (RAFi, 2 μmol/L), AZD6244 (MEKi, 200 nmol/L), PLX AZD6244, or VTX11E (ERKi, 2 μmol/L). MEK1 is a negative control; RAF1 is a positive control for RAFi resistance. Data are mean ± standard deviation. Asterisks beneath graph indicate P < 0.01 (two-tailed t test) relative to the same cell line, expressing MEK1, and treated with the same drug. B, effects of AXL overexpression on phosphorylation of AKT and maintenance of ERK phosphorylation following overnight treatment with MAPK pathway inhibitors. D, DMSO; P, 2 μmol/L PLX4720; A, 200 nmol/L AZD6244; PA, PLX AZD6244; and E, VTX11E, 2 μmol/L. MEK1 is a negative control; RAF1 is a positive control for pERK reactivation following RAFi treatment. C, effects of AXL inhibitors on induction of pAKT and rescue of pERK following AXL overexpression. R428, 500 nmol/L; XL184, 3 μmol/L; XL880, 100 nmol/L; in the presence or absence of 2 μmol/L PLX4720. shAXL is a positive control. D, effects of AXL inhibitors on pAKT and pERK levels in intrinsically resistant cell lines in the presence or absence of PLX4720. E, effects of AXL inhibitors on intrinsic resistance to PLX4720. David J. Konieczkowski et al. Cancer Discovery 2014;4: ©2014 by American Association for Cancer Research

Download ppt "AXL is not necessary for maintenance of intrinsic resistance."

Similar presentations

Functional role of Pak1/Erk signaling in Rac-related diseases Daniela Araiza-Olivera, Jennifer Rhodes, and Jonathan Chernoff FOX CHASE CANCER CENTER, 333.

Functional role of Pak1/Erk signaling in Rac-related diseases Daniela Araiza-Olivera, Jennifer Rhodes, and Jonathan Chernoff FOX CHASE CANCER CENTER, 333.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
MAPK pathway inhibitors.

MAPK pathway inhibitors.
Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.
PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.
Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.
RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.

RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.
AKT dependence of ovarian cancer cell lines.

AKT dependence of ovarian cancer cell lines.
Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M

Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M
by Reuben Kapur, Ryan Cooper, Lei Zhang, and David A. Williams

by Reuben Kapur, Ryan Cooper, Lei Zhang, and David A. Williams
NF1 downregulation activates MAPK pathway signaling.

NF1 downregulation activates MAPK pathway signaling.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.
Volume 29, Issue 3, Pages (March 2016)

Volume 29, Issue 3, Pages (March 2016)
Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.
A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.
Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.
p38 MAPK activation is required for phosphorylation of Akt at Ser473.

p38 MAPK activation is required for phosphorylation of Akt at Ser473.
BRAF inhibitor-resistant BRAF-mutant melanoma cells show increased invasion and metastatic potential. BRAF inhibitor-resistant BRAF-mutant melanoma cells.

BRAF inhibitor-resistant BRAF-mutant melanoma cells show increased invasion and metastatic potential. BRAF inhibitor-resistant BRAF-mutant melanoma cells.
AMPK induces VEGF-A production by upregulating ERK signaling.

AMPK induces VEGF-A production by upregulating ERK signaling.

Similar presentations

Ads by Google